Trial watch - inhibiting PARP enzymes for anticancer therapy

Area of Science:

• Biochemistry and Molecular Biology
• Cancer Biology
• Genetics

Background:

• Poly(ADP-ribose) polymerases (PARPs) are enzymes involved in DNA damage response (DDR) and other cellular processes.
• PARP1, a key family member, is activated by DNA damage and aids in repair by modifying DDR proteins.
• While PARP1 can promote cell survival and genomic stability, its upregulation is observed in various cancers.

Purpose of the Study:

• To elucidate the role of PARP enzymes and PARylation in cancer development and progression.
• To discuss the mechanisms by which PARP1 inactivation leads to cancer cell death.
• To summarize recent clinical trial findings on the safety and efficacy of PARP inhibitors in cancer patients.

Main Methods:

• Review of existing preclinical and clinical studies on PARP inhibitors.
• Analysis of the molecular mechanisms of PARylation and its impact on DNA repair.
• Synthesis of data from clinical trials evaluating PARP inhibitors in various cancer types.

Main Results:

• PARP inhibitors demonstrate potent antineoplastic activity, particularly in homologous recombination-deficient ovarian and breast cancers.
• Inactivation of PARP1 triggers cancer cell death through specific molecular pathways.
• Clinical studies indicate a therapeutic potential for PARP inhibitors, with assessed safety and efficacy profiles.

Conclusions:

• PARP enzymes play a dual role in cancer, with potential oncosuppressive functions but also involvement in neoplastic progression.
• PARP inhibitors represent a promising targeted therapy for specific cancer types, especially those with DNA repair defects.
• Ongoing clinical evaluations are crucial for defining the therapeutic landscape of PARP inhibitors in oncology.